O
Ole Erik Iversen
Researcher at University of Bergen
Publications - 33
Citations - 3997
Ole Erik Iversen is an academic researcher from University of Bergen. The author has contributed to research in topics: Cervical intraepithelial neoplasia & Population. The author has an hindex of 24, co-authored 32 publications receiving 3505 citations. Previous affiliations of Ole Erik Iversen include University of Virginia & Haukeland University Hospital.
Papers
More filters
Journal ArticleDOI
A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women
Elmar A. Joura,Anna R. Giuliano,Ole Erik Iversen,Céline Bouchard,Constance Mao,Jesper Mehlsen,Edson D. Moreira,Yuen Ngan,Lone Kjeld Petersen,Eduardo Lazcano-Ponce,Punnee Pitisuttithum,Jaime Alberto Restrepo,Gavin Stuart,Linn Woelber,Yuh Cheng Yang,Jack Cuzick,Suzanne M. Garland,Warner K. Huh,Susanne K. Kjaer,Oliver Bautista,Ivan S. F. Chan,Joshua Chen,Richard Gesser,Erin Moeller,Michael Ritter,Scott Vuocolo,Alain Luxembourg +26 more
TL;DR: The 9vHPV vaccine prevented infection and disease related to HPV-31, 33, 45, 52, and 58 in a susceptible population and generated an antibody response to HPV -6, 11, 16, and 18 that was noninferior to that generated by the qHPV Vaccine.
Journal ArticleDOI
Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young Women
Nubia Muñoz,Susanne K. Kjaer,Kristjan Sigurdsson,Ole Erik Iversen,Mauricio Hernández-Ávila,Cosette M. Wheeler,Gonzalo Perez,Gonzalo Perez,Darron R. Brown,Laura A. Koutsky,Eng Tay,Patricia J. Garcia,Kevin A. Ault,Suzanne M. Garland,Suzanne M. Garland,Sepp Leodolter,Sven Eric Olsson,Grace W.K. Tang,Daron G. Ferris,Jorma Paavonen,Marc Steben,F. Xavier Bosch,Joakim Dillner,Warner K. Huh,Elmar A. Joura,Robert J. Kurman,Slawomir Majewski,Evan R. Myers,Luisa L. Villa,Frank J. Taddeo,Christine C. Roberts,Amha Tadesse,Janine T. Bryan,Lisa Lupinacci,Katherine E.D. Giacoletti,Heather L. Sings,Margaret James,Teresa M. Hesley,Eliav Barr,Richard M. Haupt +39 more
TL;DR: High-coverage HPV vaccination programs among adolescents and young women may result in a rapid reduction of genital warts, cervical cytological abnormalities, and diagnostic and therapeutic procedures and in the longer term, substantial reductions in the rates of cervical, vulvar, and vaginal cancers may follow.
Journal ArticleDOI
Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.
Joakim Dillner,Joakim Dillner,Susanne K. Kjaer,Cosette M. Wheeler,Kristjan Sigurdsson,Ole Erik Iversen,Mauricio Hernández-Ávila,Gonzalo Perez,Darron R. Brown,Laura A. Koutsky,Eng Tay,Patricia J. Garcia,Kevin A. Ault,Suzanne M. Garland,Sepp Leodolter,Sven Eric Olsson,Grace W.K. Tang,Daron G. Ferris,Jorma Paavonen,Matti Lehtinen,Marc Steben,F. Xavier Bosch,Elmar A. Joura,Slawomir Majewski,Nubia Muñoz,Evan R. Myers,Luisa L. Villa,Frank J. Taddeo,Christine C. Roberts,Amha Tadesse,Janine T. Bryan,Roger Maansson,Shuang Lu,Scott Vuocolo,Teresa M. Hesley,Eliav Barr,Richard M. Haupt +36 more
TL;DR: Quadrivalent HPV vaccine provided sustained protection against low grade lesions attributable to vaccine HPV types and a substantial reduction in the burden of these diseases through 42 months of follow-up.
Journal ArticleDOI
Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial
Warner K. Huh,Elmar A. Joura,Anna R. Giuliano,Ole Erik Iversen,Ole Erik Iversen,Rosires Pereira de Andrade,Kevin A. Ault,Deborah Bartholomew,Ramon M. Cestero,Edison Natal Fedrizzi,Angelica Lindén Hirschberg,Marie-Hélène Mayrand,Ángela María Ruiz-Sternberg,Jack T. Stapleton,Jack T. Stapleton,Dorothy J. Wiley,Alex Ferenczy,Robert J. Kurman,Brigitte M. Ronnett,Mark H. Stoler,Jack Cuzick,Suzanne M. Garland,Susanne K. Kjaer,Oliver Bautista,Richard M. Haupt,Erin Moeller,Michael Ritter,Christine C. Roberts,Christine Shields,Alain Luxembourg +29 more
TL;DR: The 9vHPV vaccine prevents infection, cytological abnormalities, high-grade lesions, and cervical procedures related to HPV 31, 33, 45, 52, and 58, and non-inferior HPV 6, 11, 16, and 18 antibody responses when compared with quadrivalent HPV (qHPV).
Journal ArticleDOI
Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection.
Sven Eric Olsson,Susanne K. Kjaer,Kristjan Sigurdsson,Ole Erik Iversen,Mauricio Hernández-Ávila,Cosette M. Wheeler,Gonzalo Perez,Darron R. Brown,Laura A. Koutsky,Eng Tay,Patricia J. Garcia,Kevin A. Ault,Suzanne M. Garland,Sepp Leodolter,Grace W.K. Tang,Daron G. Ferris,Jorma Paavonen,Matti Lehtinen,Marc Steben,F. Xavier Bosch,Joakim Dillner,Elmar A. Joura,Slawomir Majewski,Nubia Muñoz,Evan R. Myers,Luisa L. Villa,Frank J. Taddeo,Christine C. Roberts,Amha Tadesse,Janine T. Bryan,Roger Maansson,Scott Vuocolo,Teresa M. Hesley,Alfred J. Saah,Eliav Barr,Richard M. Haupt +35 more
TL;DR: It is suggested that natural HPV infection-elicited antibodies may not provide complete protection over time, however the immune response to the HPV 6/11/16/18 vaccine appears to prevent reinfection or reactivation of disease with vaccine HPV types.